Skip to main content
Contact Us
Subscribe
E-Edition
40°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Archives
Best of 2025
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Personalis, Inc. - Common Stock
(NQ:
PSNL
)
5.510
+0.520 (+10.42%)
Streaming Delayed Price
Updated: 4:00 PM EST, Feb 14, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Personalis, Inc. - Common Stock
< Previous
1
2
3
4
5
Next >
Personalis to Announce Fourth Quarter and Full Year 2024 Financial Results
February 13, 2025
From
Personalis, Inc.
Via
Business Wire
Personalis to Participate at the BTIG Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
January 28, 2025
From
Personalis, Inc.
Via
Business Wire
New Nature Medicine Publication Shows ctDNA Levels Linked to Recurrence Risk in Lung Cancer
January 13, 2025
From
Personalis, Inc.
Via
Business Wire
Personalis Reports Preliminary Fourth Quarter and Full Year 2024 Revenue
January 07, 2025
From
Personalis, Inc.
Via
Business Wire
Oncology Advancements Accelerate Amid Rising Early-Onset Cancer Diagnoses
December 20, 2024
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:CRDF),(NASDAQ:PSNL),(NASDAQ:TEM),(NASDAQ:CKPT) EQNX::TICKER_END
Via
FinancialNewsMedia
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
COVID-19
Personalis Advances Business Strategy with Investment from Merck and Extends Collaboration with Moderna
December 19, 2024
From
Personalis, Inc.
Via
Business Wire
Personalis and Tempus Expand Collaboration to Biopharma
December 16, 2024
From
Personalis, Inc.
Via
Business Wire
Personalis to Participate at Upcoming Investor Conferences
November 20, 2024
From
Personalis, Inc.
Via
Business Wire
Personalis Reports Third Quarter 2024 Financial Results
November 06, 2024
From
Personalis, Inc.
Via
Business Wire
Personalis to Present at the Stifel 2024 Healthcare Conference
November 05, 2024
From
Personalis, Inc.
Via
Business Wire
Personalis to Announce Third Quarter 2024 Financial Results
October 23, 2024
From
Personalis, Inc.
Via
Business Wire
ESMO 2024 Data Expands on Compelling Performance of Personalis NeXT Personal® MRD Test
September 16, 2024
From
Personalis, Inc.
Via
Business Wire
Biotech Stock Soars 60% in 2024: Cathie Wood’s Bold Investment
August 23, 2024
Tempus AI is a hot healthcare stock that investors should be aware of. It is using AI to pursue "precision medicine", especially in cancer research.
Via
MarketBeat
Topics
Artificial Intelligence
ETFs
Exposures
Artificial Intelligence
Personalis to Participate at Upcoming Investor Conferences
August 22, 2024
From
Personalis, Inc.
Via
Business Wire
Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 19, 2024
From
Personalis, Inc.
Via
Business Wire
Personalis and Tempus Announce Expanded Collaboration
August 16, 2024
From
Personalis, Inc.
Via
Business Wire
Personalis Reports Second Quarter 2024 Financial Results
August 07, 2024
From
Personalis, Inc.
Via
Business Wire
Myriad Genetics Reports Strong Second Quarter 2024 Financial Results, including 15% Revenue Growth Year-Over-Year; Raises 2024 Financial Guidance and Long-Term Revenue Growth Target to 12%
August 06, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Personalis to Participate at the 9th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference
July 31, 2024
From
Personalis, Inc.
Via
Business Wire
Personalis to Announce Second Quarter 2024 Financial Results
July 24, 2024
From
Personalis, Inc.
Via
Business Wire
Myriad Genetics and Personalis Cross-License Foundational MRD Intellectual Property to Broaden Patient Access to Testing
July 11, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Personalis to Participate at the TD Cowen 3rd Annual Tools / Dx Revolution Conference
June 18, 2024
From
Personalis, Inc.
Via
Business Wire
Personalis Provides Dial-in and Updated Date for ASCO Highlights Conference Call
June 13, 2024
From
Personalis, Inc.
Via
Business Wire
ASCO Data Highlights NeXT Personal® Ultra-sensitive MRD Performance in Early-stage Breast Cancer Recurrence Detection and Immunotherapy Monitoring
June 04, 2024
From
Personalis, Inc.
Via
Business Wire
Personalis Announces Start of Cancer MRD Testing Commercialization Collaboration with Tempus
May 31, 2024
From
Personalis, Inc.
Via
Business Wire
Personalis Announces Podium Presentations and Abstracts Accepted at ASCO 2024
May 22, 2024
From
Personalis, Inc.
Via
Business Wire
Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 17, 2024
From
Personalis, Inc.
Via
Business Wire
Personalis Reports First Quarter 2024 Financial Results
May 08, 2024
From
Personalis, Inc.
Via
Business Wire
Personalis to Announce First Quarter 2024 Financial Results
April 24, 2024
From
Personalis, Inc.
Via
Business Wire
Personalis to Present at the 23rd Annual Needham Virtual Healthcare Conference
March 28, 2024
From
Personalis, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
